Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

PharmacoEconomics - open·2026

Same author

Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events.

Journal of the National Cancer Institute·2026

Same author

A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population.

Journal of medical economics·2025

Same author

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer.

Cancer medicine·2025

Same author

Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.

International journal of cancer·2025

Search research articles

Related Experiment Video

Updated: Jan 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Biosimilars: what the oncologist should know.

Marc Thill¹, Nicholas Thatcher², Vladimir Hanes³

¹Department of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt am Main, Germany.

Future Oncology (London, England)

|February 23, 2019

Summary

This summary is machine-generated.

Biosimilars offer more affordable biologic medicine options as patents expire. This review helps clinicians understand biosimilar development, use, and differences from originator biologics and generics, especially in oncology.

Keywords:

biosimilars extrapolation monoclonal antibodies oncologic biosimilars

More Related Videos

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

Identification of Fatty Acids in Bacillus cereus

Identification of Fatty Acids in Bacillus cereus

Published on: December 5, 2016

Related Experiment Videos

Last Updated: Jan 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

Identification of Fatty Acids in Bacillus cereus

Identification of Fatty Acids in Bacillus cereus

Published on: December 5, 2016

Area of Science:

Biopharmaceutical development
Oncology therapeutics
Regulatory science

Background:

Originator biologic medicines face patent expiration, creating opportunities for biosimilar development.
Biosimilars are similar, complex biologic therapies designed to be more affordable.
Increasing global approval and future introduction of biosimilars necessitate clinical understanding.

Purpose of the Study:

To educate practicing clinicians on biosimilar medicines.
To explain the development process of biosimilars compared to originator biologics.
To guide the clinical use of biosimilars in oncologic diseases.

Main Methods:

Literature review of biosimilar development and regulatory pathways.
Comparative analysis of biosimilar and originator biologic characteristics.
Synthesis of current evidence on biosimilar application in oncology.

Main Results:

Biosimilar development involves rigorous analytical, clinical, and non-clinical studies to demonstrate similarity.
Key differences exist in development pathways compared to generic drugs.
Evidence supports the efficacy and safety of biosimilars in various oncologic indications.

Conclusions:

Clinicians require knowledge of biosimilar development and regulatory standards.
Biosimilars represent a viable, cost-effective alternative to originator biologics in cancer care.
Familiarity with biosimilars is crucial for expanding access to advanced therapies.